New Pain Treatment Triumphs Morphine (OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS) through their wholly owned subsidiary, ReceptoPharm Inc. With billions of dollars in potential target markets, Nutra Pharma is one company which is ready to take the biopharmaceuticals sector by storm.

About

Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company’s wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company’s other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Midterm goal

Nutra Pharma Corp’s midterm strategy for the past three years has been to license Nutra Pharma Corp’s AMN, MS and HIV technologies in Nutra Pharma Corp’s attempt to bring these technologies to market within 5 years. Should Nutra Pharma Corp. obtain adequate financing, Nutra Pharma Corp’s midterm strategy remains the same— to accomplish these midterm goals in the next two years of that 5 year period.

Long-term goal

Nutra Pharma Corp’s long-term goal is the use of drugs developed by ReceptoPharm and future affiliates in the field of neurological diseases, infectious diseases and autoimmune disorders. Due to Nutra Pharma Corp’s limited financial and operational resources, this goal will require Nutra Pharma Corp. to establish strategic partners or alliances with pharmaceutical companies, academic institutions, biotechnology companies, and clinical diagnostic laboratories, which will: (a) complement Nutra Pharma Corp’s research and development efforts; (b) reduce the risks associated with undertaking the entire process of drug development and marketing; and (c) generate licensing based revenue streams.

The full special report on the company appears today at http://www.stockshaven.com/new-pain-treatment-triumphs-morphine-otcnphc/

Disclosure: Position in NPHC

To feature a publicly traded company in StocksHaven.com Alerts or as a fully profiled company, email us at michaelvlaicu@stockshaven.com or visit http://www.stockshaven.com/ir_contract/ for more info

About StocksHaven Investments

StocksHaven Investments can be found at StocksHaven.com. It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, mass e-mail distribution alerts, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers Investor Relations contracting services.

For more financial and investment news, visit www.StocksHaven.com

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

Contact Information

Michael Vlaicu

Founder and Lead Investment Analyst

StocksHaven Investments

Contact via E-mail